AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8416458 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectinomycin 2 g IM
Number of subjects: 252
Study 2877490 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS), 120 mg 4 times a day
Number of subjects: 43
Study 2877490 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (C), 400 mg 3 times a day
Number of subjects: 43
Study 2877490 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (C), 400 mg at meals plus 800 mg at bedtime
Number of subjects: 43
Study 30173431 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U botulinum‐A toxin at 10 U/ml
Number of subjects: 70
Study 30173431 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U botulin‐A toxin at 10 U/ml
Number of subjects: 70
Study 30173431 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 70
Study 26927315 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 151
Study 26927315 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction (1 kg)
Number of subjects: 151
Study 26927315 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 151
Study 25073131 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of amplification and sound generator
Number of subjects: 49
Study 25073131 — intervention group
Group type: COMPARATOR
Intervention: Conventional amplification alone
Number of subjects: 49
Study 22712629 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 5 mg once daily, titrated to 10 mg twice daily for 11 days, then DMQ 30 mg every 12 hours for 8 days
Number of subjects: 52
Study 22712629 — intervention group
Group type: EXPERIMENTAL
Intervention: DMQ 30 mg every 12 hours for 8 days, then memantine titrated to 10 mg every 12 hours for 11 days
Number of subjects: 52
Study 22712629 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (part of DMQ)
Number of subjects: 52
Study 22712629 — intervention group
Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 52
Study 22712629 — intervention group
Group type: COMPARATOR
Intervention: Pharmacodynamic variables
Number of subjects: 52
Study 20154601 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial catheters
Number of subjects: 3532
Study 20154601 — intervention group
Group type: COMPARATOR
Intervention: Central venous catheters
Number of subjects: 3532
Study 18587135 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 at 4.5 MIU twice daily in 5 day cycles
Number of subjects: 36
Study 18587135 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 at 7.5 MIU twice daily in 5 day cycles
Number of subjects: 36
Study 18587135 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 36
Study 18587135 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2
Number of subjects: 36
Study 18587135 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IL-2
Number of subjects: 36
Study 18587135 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 36
Study 15891326 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ITD on facemask
Number of subjects: 13
Study 15891326 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ITD on ETT
Number of subjects: 13
Study 15891326 — intervention group
Group type: COMPARATOR
Intervention: Sham ITD on facemask
Number of subjects: 13
Study 15891326 — intervention group
Group type: COMPARATOR
Intervention: Sham ITD on ETT
Number of subjects: 13
Study 11788552 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml meat soup meal
Number of subjects: 40
Study 11788552 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 9895382 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG (13 g/sachet)
Number of subjects: 115
Study 9895382 — intervention group
Group type: COMPARATOR
Intervention: Lactulose (10 g/sachet)
Number of subjects: 115
Study 8562673 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 ml/kg alcohol
Number of subjects: 8
Study 8562673 — intervention group
Group type: COMPARATOR
Intervention: non-alcoholic drink
Number of subjects: 8
Study 2371929 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg)
Number of subjects: 114
Study 2371929 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg)
Number of subjects: 114
Study 2371929 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (30 ml)
Number of subjects: 114
Study 2371929 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study 7395881 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis
Number of subjects: 27
Study 7395881 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infiltration
Number of subjects: 27
Study 7395881 — intervention group
Group type: COMPARATOR
Intervention: Topical application of lidocaine or placebo
Number of subjects: 27
Study 31987229 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day of synbiotic for 8 weeks
Number of subjects: 60
Study 31987229 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 60
Study 31407653 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual community-wide treatment (CWT) for four years
Number of subjects: 0
Study 31407653 — intervention group
Group type: COMPARATOR
Intervention: Biennial school-based treatment (SBT) over four years
Number of subjects: 0
Study 28300854 — intervention group
Group type: EXPERIMENTAL
Intervention: THVD-102 (oxybutynin 7.5 mg / pilocarpine 7.5 mg)
Number of subjects: 24
Study 28300854 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 7.5 mg
Number of subjects: 24
Study 28300854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28300854 — intervention group
Group type: EXPERIMENTAL
Intervention: THVD-102
Number of subjects: 24
Study 28300854 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 24
Study 26529009 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal proteins (zein, gliadin, glutelin)
Number of subjects: 30
Study 26529009 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume proteins (soy, pea, lentil)
Number of subjects: 30
Study 26529009 — intervention group
Group type: COMPARATOR
Intervention: Control (heme alone)
Number of subjects: 30
Study 23640731 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront double-guidewire technique (DGT)
Number of subjects: 50
Study 23640731 — intervention group
Group type: COMPARATOR
Intervention: Standard cannulation technique (SCT)
Number of subjects: 50
Study 21614940 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulpa dentis D30 (PD)
Number of subjects: 32
Study 19285658 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgisis Inguinal Hernia Matrix (SIHM)
Number of subjects: 70
Study 19285658 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene (PP)
Number of subjects: 70
Study 16581983 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS applied to right dorsal extrastriate cortex in EB subjects
Number of subjects: 0
Study 16581983 — intervention group
Group type: COMPARATOR
Intervention: rTMS targeting the same cortical areas in sighted subjects
Number of subjects: 0
Study 15605184 — intervention group
Group type: EXPERIMENTAL
Intervention: IV/PO moxifloxacin (400 mg q.i.d.)
Number of subjects: 101
Study 15605184 — intervention group
Group type: COMPARATOR
Intervention: IV/PO antimicrobial comparator agents
Number of subjects: 101
Study 11408428 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training under hypoxic conditions
Number of subjects: 4
Study 11408428 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity training under hypoxic conditions
Number of subjects: 4
Study 11408428 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training under normoxic conditions
Number of subjects: 4
Study 11408428 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity training under normoxic conditions
Number of subjects: 4
Study 11408428 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4
Study 9005910 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative epidural infusion of 5 microg/ml fentanyl
Number of subjects: 19
Study 9005910 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative epidural infusion of 5 microg/ml fentanyl plus 0.125% bupivacaine at a rate of 10 ml per hour
Number of subjects: 19
Study 9005910 — intervention group
Group type: EXPERIMENTAL
Intervention: Active flexion and extension of the foot
Number of subjects: 19
Study 8238138 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 93
Study 8238138 — intervention group
Group type: COMPARATOR
Intervention: Narcotic analgesia
Number of subjects: 93
Study 3306943 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam (n = 29)
Number of subjects: 60
Study 3306943 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin plus tobramycin (n = 31)
Number of subjects: 60
Study 31229619 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral GABA twice daily plus two injections of recombinant GAD enzyme
Number of subjects: 99
Study 31229619 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral GABA plus placebo GAD injections
Number of subjects: 99
Study 31229619 — intervention group
Group type: COMPARATOR
Intervention: Placebo GABA and placebo GAD
Number of subjects: 99
Study 29485791 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA with a mixture of levobupivacaine, fentanyl and adrenaline
Number of subjects: 60
Study 29485791 — intervention group
Group type: COMPARATOR
Intervention: IV‐PCA with morphine
Number of subjects: 60
Study 25604760 — intervention group
Group type: EXPERIMENTAL
Intervention: Community workshops, community involvement in clean-up campaigns, covering elevated containers, in-house rubbish disposal without larviciding, mobilization of schoolchildren and senior inhabitants, distribution of IEC materials
Number of subjects: 20
Study 25604760 — intervention group
Group type: COMPARATOR
Intervention: Routine vector control activities
Number of subjects: 20
Study 23243173 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal clindamycin
Number of subjects: 450
Study 23243173 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus-vaginal probiotic
Number of subjects: 450
Study 23243173 — intervention group
Group type: COMPARATOR
Intervention: Vaginal placebo
Number of subjects: 450
Study 23243173 — intervention group
Group type: EXPERIMENTAL
Intervention: Same pre-/posttreatment sexual partner
Number of subjects: 450
Study 23243173 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsistent condom use
Number of subjects: 450
Study 23243173 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Australian
Number of subjects: 450
Study 23243173 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-containing contraceptive
Number of subjects: 450
Study 22254399 — intervention group
Group type: EXPERIMENTAL
Intervention: Model DBS
Number of subjects: 5
Study 22254399 — intervention group
Group type: COMPARATOR
Intervention: Clinical DBS
Number of subjects: 5
Study 22254399 — intervention group
Group type: COMPARATOR
Intervention: Off DBS
Number of subjects: 5
Study 19811638 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus the training (Future oriented group training)
Number of subjects: 0
Study 16673803 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate (MAL)
Number of subjects: 69
Study 16673803 — intervention group
Group type: COMPARATOR
Intervention: Aminolevulinic acid (ALA)
Number of subjects: 69
Study 15657666 — intervention group
Group type: EXPERIMENTAL
Intervention: PTP injection into intersphincteric space and internal anal sphincter with guidance by endoanal ultrasound (Group A, n = 42)
Number of subjects: 82
Study 15657666 — intervention group
Group type: COMPARATOR
Intervention: PTP injection into intersphincteric space and internal anal sphincter without guidance by endoanal ultrasound (Group B, n = 40)
Number of subjects: 82
Study 11145794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment (0.03% or 0.1%)
Number of subjects: 631
Study 11145794 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 631
Study 9761513 — intervention group
Group type: EXPERIMENTAL
Intervention: RenaGel (calcium- and aluminium-free phosphate binder), starting doses of one, two, or three 500-mg capsules three times per day with meals for 8 weeks.
Number of subjects: 0
Study 9761513 — intervention group
Group type: EXPERIMENTAL
Intervention: RenaGel treatment
Number of subjects: 0
Study 7800969 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-85 BV (oral administration)
Number of subjects: 0
Study 7800969 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-85 BV (injection)
Number of subjects: 0
Study 3364402 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-A (320-400 nm) doses of 17.8 +/- 1.9 J/cm2 to the anterior side and 21.0 +/- 3.3 J/cm2 to the posterior side, with UV-B (280-320 nm) doses equivalent to 10% of UV-A doses.
Number of subjects: 24
Study 31356810 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0-mm ultrathin bronchoscope (UTB)
Number of subjects: 356
Study 31356810 — intervention group
Group type: COMPARATOR
Intervention: 4.0-mm thin bronchoscope
Number of subjects: 356
Study 28532870 — intervention group
Group type: EXPERIMENTAL
Intervention: High repetitive, high dosage medical exercise therapy (MET), n=16
Number of subjects: 33
Study 28532870 — intervention group
Group type: COMPARATOR
Intervention: Low dosage exercise therapy (ET), n=17
Number of subjects: 33
Study 25466662 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplements (600 kcal, 20 g/d protein) and intensive rehabilitation program
Number of subjects: 200
Study 25466662 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 200
Study 25466662 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplements and rehabilitation program
Number of subjects: 200
Study 23315099 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy with CA 19-9, CEA, CRP, LDH, and bilirubin levels assessed before treatment and during treatment (for CA 19-9 only)
Number of subjects: 291
Study 23315099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment CA 19-9 levels
Number of subjects: 291
Study 23315099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment LDH levels
Number of subjects: 291
Study 23315099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment CEA levels
Number of subjects: 291
Study 23315099 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CA 19-9 levels
Number of subjects: 291
Study 23315099 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CRP levels
Number of subjects: 291
Study 23315099 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline bilirubin levels
Number of subjects: 291
Study 23315099 — intervention group
Group type: EXPERIMENTAL
Intervention: Log [CA 19-9] as a continuous variable
Number of subjects: 291
Study 23315099 — intervention group
Group type: EXPERIMENTAL
Intervention: Log [bilirubin] and log [CRP]
Number of subjects: 291
Study 23315099 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 19-9 decline of ≥25% during the first two chemotherapy cycles
Number of subjects: 291
Study 19744201 — intervention group
Group type: EXPERIMENTAL
Intervention: Chin bone augmentation
Number of subjects: 93
Study 19744201 — intervention group
Group type: EXPERIMENTAL
Intervention: Chin bone covered by Bio-Gide® membrane
Number of subjects: 93
Study 19744201 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Oss® covered by Bio-Gide® membrane
Number of subjects: 93
Study 19744201 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (combined)
Number of subjects: 93
Study 19581545 — intervention group
Group type: EXPERIMENTAL
Intervention: Project ALERT intervention (manualized classroom-based substance use prevention curriculum)
Number of subjects: 5883
Study 19581545 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 5883
Study 17094382 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential anthracycline-docetaxel regimen
Number of subjects: 98
Study 17094382 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the ADEBAR study
Number of subjects: 98
Study 17094382 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy with anthracyclines
Number of subjects: 98
Study 15087630 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg preoperatively
Number of subjects: 50
Study 15087630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11702034 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent moderate-intensity physical activity (10 min, three times a day, 5 days per week at 50-60% heart rate reserve)
Number of subjects: 18
Study 11702034 — intervention group
Group type: COMPARATOR
Intervention: No change in physical activity
Number of subjects: 18
Study 9325503 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐declared spontaneous quitters
Number of subjects: 599
Study 9325503 — intervention group
Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 599
Study 7934143 — intervention group
Group type: EXPERIMENTAL
Intervention: MM BM stromal cells
Number of subjects: 3
Study 7934143 — intervention group
Group type: COMPARATOR
Intervention: MGUS BM stromal cells
Number of subjects: 3
Study 7934143 — intervention group
Group type: COMPARATOR
Intervention: Normal donor BM stromal cells
Number of subjects: 3
Study 3135737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue‐type plasminogen activator (rt‐PA)
Number of subjects: 0
Study 3135737 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase (SK)
Number of subjects: 0
Study 3135737 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (timing before or after 4 hours of AMI onset)
Number of subjects: 0
Study 3135737 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with patent arteries 90 minutes after therapy initiation
Number of subjects: 0
Study 29129784 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable partial dental prostheses (RPDP)
Number of subjects: 89
Study 29129784 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened dental arch (SDA)
Number of subjects: 89
Study 29129784 — intervention group
Group type: COMPARATOR
Intervention: Both RPDP and SDA
Number of subjects: 89
Study 27236703 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing (VCF)
Number of subjects: 93
Study 27236703 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 93
Study 26255173 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-lesson intervention
Number of subjects: 125
Study 26255173 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 125
Study 24469138 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen inhalation sedation
Number of subjects: 72
Study 24469138 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitrous oxide/oxygen inhalation sedation)
Number of subjects: 72
Study 21835201 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeleton projection-based approach
Number of subjects: 0
Study 21835201 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniform (DC) offset between two groups
Number of subjects: 0
Study 18307586 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + SSRI
Number of subjects: 150
Study 18307586 — intervention group
Group type: COMPARATOR
Intervention: SSRI
Number of subjects: 150
Study 18307586 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 150
Study 22311406 — intervention group
Group type: EXPERIMENTAL
Intervention: Feitai Capsule (1.2 g/capsule, 4 capsules, 3 times a day for 3 weeks, followed by 1 week off, continued for at least 3 more cycles, totaling 12 weeks)
Number of subjects: 62
Study 22311406 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular follow-up and evaluation every 8 weeks until PD)
Number of subjects: 62
Study 15960643 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 ml.kg(‐1) bupivacaine 0.25% plus 1 microg.kg(‐1) clonidine
Number of subjects: 98
Study 15960643 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% alone
Number of subjects: 98
Study 15960643 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 98
Study 12580705 — intervention group
Group type: EXPERIMENTAL
Intervention: Premarin (conjugated equine estrogen) 0.625 mg/d
Number of subjects: 120
Study 12580705 — intervention group
Group type: EXPERIMENTAL
Intervention: Premarin (conjugated equine estrogen) 1.25 mg/d
Number of subjects: 120
Study 10204895 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinocath
Number of subjects: 60
Study 10204895 — intervention group
Group type: COMPARATOR
Intervention: Intralong
Number of subjects: 60
Study 7779441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipecacuanha-induced emesis
Number of subjects: 12
Study 7779441 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric lavage
Number of subjects: 12
Study 7779441 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral activated charcoal
Number of subjects: 12
Study 7779441 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 12
Study 2077584 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD 10 TU
Number of subjects: 322
Study 2077584 — intervention group
Group type: COMPARATOR
Intervention: PPD 2 TU
Number of subjects: 322
Study 2077584 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster effect from second tuberculin test
Number of subjects: 322
Study 312366 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (500 mg added to each liter of cardioplegic solution)
Number of subjects: 22
Study 312366 — intervention group
Group type: COMPARATOR
Intervention: Control group (no methylprednisolone added)
Number of subjects: 22
Study 12006932 — intervention group
Group type: EXPERIMENTAL
Intervention: HspE7 (500 microg monthly for 3 months)
Number of subjects: 22
Study 31256250 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Skills Acquisition Protocol (ASAP)
Number of subjects: 16
Study 31256250 — intervention group
Group type: COMPARATOR
Intervention: Conventional Training Protocol (CTP)
Number of subjects: 16
Study 29481992 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicate-based wound dressing (DermFactor®) combined with conventional dressing therapy
Number of subjects: 328
Study 29481992 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing therapy
Number of subjects: 328